When was ValenTx founded?

ValenTx was founded in 2002 and raised its 1st funding round 4 years after it was founded.

Where is ValenTx located?

ValenTx is headquartered in Carpinteria, United States.

How many employees does ValenTx have?

As of Apr 30, 2026, the latest employee count at ValenTx is 9.

Is ValenTx a funded company?

ValenTx is a funded company, having raised a total of $48.7M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 2006.

When was the latest funding round of ValenTx?

ValenTx's latest funding was a $***** Series B round on Feb 19, 2019, with participation from 0 investor. Its primary sector is Obesity. In United States, the Obesity sector has seen $340M in funding in 2026 to date.

Where does ValenTx rank among its competitors?

ValenTx ranks 7th amongst 8 active competitors, of which 4 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was ModaThera, which secured $331K in Apr, 2025.

Who are the top competitors of ValenTx?

ValenTx's top competitors include GI Windows, ModaThera and GT Metabolic Solutions. Among them, ModaThera secured the most recent funding round in April, 2025.

ValenTx - 2026 Company Profile, Team, Funding & Competitors

ValenTx is a deadpooled company based in Carpinteria (United States), founded in 2002. It operates as an Adjustable Endoluminal bypass sleeve for obesity treatment. ValenTx has raised $48.7M in funding from EDF Ventures and SV Health Investors. The company has 8 active competitors, including 4 funded and 1 that has exited. Its top competitors include companies like GI Windows, ModaThera and GT Metabolic Solutions.

Company Details

ValenTx is a development-stage medical device company focused on minimally invasive, non-surgical approaches for the treatment of morbid obesity and related disorders such as hypertension and type-2 diabetes. The technology uses a non-surgical, adjustable, removable, and replaceable endoluminal bypass sleeve device(the ValenTx Bypass Sleeve) to treat obesity. The company claims that its device mimics the therapeutic mechanisms of a Roux-en-Y gastric bypass but obtains these with an implantable device, that does not require surgery, gastric stapling or a permanent changes to the patient's anatomy. As of 2016, the product is yet to receive FDA approval.

Key Metrics

Founded Year

2002

Location

Carpinteria, United States

Stage

Deadpooled

Total Funding

$48.7M in 5 rounds

Latest Funding Round

Series B, Feb 19, 2019, $*****

Investors

EDF Ventures & 7 more

Ranked

7^th among 8 active competitors

Employee Count

9 as on Apr 30, 2026

Similar Companies

GI Windows & 7 more

View ValenTx's full profile

ValenTx has raised a total funding of $48.7M over 5 rounds. Its first funding round was on May 2006. ValenTx has 8 institutional investors.

Here is the list of recent funding rounds of ValenTx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 19, 2019	6305824	Series B	5285517	2351364	1713689	1156739
Aug 16, 2018	8978504	Series B	4645111	7202766	3036304	4692136
Jul 15, 2014	6586718	Series B	9589409	7548576	5887147	9553399

Access funding benchmarks and valuations. Sign up today!

View details of ValenTx's funding rounds and investors

ValenTx's employee count trend

ValenTx has 9 employees as of Apr 26. Here is ValenTx's employee count trend over the years:

Uncover ValenTx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ValenTx include GI Windows, ModaThera and GT Metabolic Solutions. Here is the list of Top 10 competitors of ValenTx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	GI Windows 2012, West Bridgewater (United States), Series B	Revolutionizing surgical anastomosis with innovative magnetic technology for less invasive procedures	$92M	GT Healthcare Capital Partners, Sonder Capital ... & 7 others	50/100
2nd	ModaThera 2002, Laguna Niguel (United States), Acquired	Provider of medical devices for obesity treatment and metabolic disease management	-	HealthCor Partners, Endeavour Vision & 5 others	46/100
3rd	GT Metabolic Solutions 2020, Saint Michael (United States), Series B	Developer of medical technology intended to revolutionize gastric bypass	$23.2M	Krillion Ventures	46/100
4th	Keyron 2006, London (United Kingdom), Funding Raised	Developer of therapeutics and diagnostic device for the diabetes	-	LIFTT, Riceberg Ventures	42/100
5th	EndObetes 2015, New York City (United States), Seed	Developer of surgical access tool	-	MedTech Innovator, Biotechnology Innovation Organization ... & 1 others	37/100
6th	Hangzhou Tongee Medical Technology 2017, Hangzhou (China), Series B	Limited information available	$8.56M	Langmafeng Venture Capital, Dingxin Capital ... & 4 others	36/100
7th	ValenTx 2002, Carpinteria (United States), Deadpooled	Adjustable Endoluminal bypass sleeve for obesity treatment	$48.7M	Medtronic, Kaiser Permanente Ventures & 6 others	35/100
8th	BariaTek 2019, Paris (France), Funding Raised	Developer of minimally invasive devices to treat obesity	-	Lifeblood Capital, Bpifrance	31/100
9th	Transduodenal Concepts Germany, Unfunded	Manufacturer of endoscopically implantable sleeve prostheses for metabolic health treatment	-	-	16/100